Phaseline

Companies › IRulya Therapeutics

IRulya Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Cardiovascular, Respiratory; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LAM-001–Phase 2Pulmonary Hypertension Due to Lung Diseases and Hypoxia; Bronchiolitis Obliterans SyndromeMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06018766LAM-001Phase 2Bronchiolitis Obliterans SyndromeRespiratoryDec 2026
NCT05798923LAM-001Phase 2Pulmonary Hypertension Due to Lung Diseases and HypoxiaCardiovascularMar 2028

From the company's SEC filings

Cash and short-term investments of $116m on 2026-06-30; operating cash outflow about $54m a year; runway about 26 months at that burn, to Aug 2028; 2 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Contineum Therapeutics aTyr Pharma Braveheart Bio Rein Therapeutics Incannex Healthcare

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.